
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive June 2018 issue in an interactive PDF format.
over 8 years ago
US Maps Strategy to Reform Drug Pricingover 8 years ago
C-Suite Personality: Fit for Future?over 8 years ago
Insights for the Winover 8 years ago
Leveraging Lab Data in Advent of Personalized Marketingover 8 years ago
Asembia 2018: User-Friendly Urgencyover 8 years ago
Piecing Together the Pricing Puzzle: The Midterm Electionsover 8 years ago
Pharm Exec's Top 50 Companies 2018




